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Introduction
Breast cancer is the most common female cancer and the lead-
ing cause of cancer deaths among women in the economically 
developed countries.1-3 Treatment of breast cancer requires the 
use of multiple therapeutic modalities including radiation ther-
apy. Resistance to radiotherapy often results in treatment failure, 
particularly for loco-regional recurrence.
Hence, new therapeutic strategies are required for overcoming 
radioresistance and improving prognosis of breast cancer patients.4
So far, multiple alterations of signal transduction pathways 
have been correlated with resistance of cancer cells against con-
ventional anticancer therapies.5 Among them, the aberrant sphin-
golipid metabolism is an important mediator of both chemo- 
and radio-therapy resistance.6 The enzyme sphingosine kinase 
(SphK1) converts the pro-apoptotic, anti-proliferative ceramide 
into its pro-survival and mitogenic metabolite S1P (sphingo-
sine 1-phosphatase);7,8 high cellular levels of SphK1 can protect 
against ionizing radiation. Preclinical evidence suggests that 
pharmacological inhibition of SphK1 results in sensitization of 
human prostate cancer cells to radiotherapy.9
FTY720 is a sphingosine analog and a potent immunosup-
pressive drug currently approved for treating multiple sclero-
sis.10,11 Moreover, FTY720 has also been shown to induce apop-
tosis in multiple myeloma,12 prostate,13 breast,14 kidney,15 and 
bladder cancer cells.16
Based on this experimental evidence, we sought to analyze the 
radiosensitizing effects of FTY720 in human breast cancer cells, 
in order to clearly assess its effect on growth, proliferation, and 
apoptosis.
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Radiotherapy is one of the most effective therapeutic strategies for breast cancer patients, although its efficacy may 
be reduced by intrinsic radiation resistance of cancer cells. Recent investigations demonstrate a link between cancer 
cell radio-resistance and activation of sphingosine kinase (sphK1), which plays a key role in the balance of lipid signaling 
molecules. sphingosine kinase (sphK1) activity can alter the sphingosine-1-phosphate (s1P)/ceramide ratio leading to an 
imbalance in the sphingolipid rheostat. Fingolimod (FTY720) is a novel sphingosine analog and a potent immunosup-
pressive drug that acts as a sphK1 antagonist, inhibits the growth, and induces apoptosis in different human cancer 
cell lines. We sought to investigate the in vitro radiosensitizing effects of FTY720 on the MDa-MB-361 breast cancer 
cell line and to assess the effects elicited by radiation and FTY720 combined treatments. We found that FTY720 signifi-
cantly increased anti-proliferative and pro-apoptotic effects induced by a single dose of ionizing radiation while causing 
autophagosome accumulation. at the molecular level, FTY720 significantly potentiated radiation effects on perturbation 
of signaling pathways involved in regulation of cell cycle and apoptosis, such as PI3K/aKT and MaPK. In conclusion, our 
data highlight a potent radiosensitizing effect of FTY720 on breast cancer cells and provide the basis of novel therapeutic 
strategies for breast cancer treatment.
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Results
Effects of FTY720 and ionizing radiations on MDA-
MB-361 breast cancer cells
Trypan blue exclusion assay was used to determine the effects 
of FTY720, either alone or in combination with radiation, on cell 
proliferation in vitro. Ionizing radiation caused a dose-dependent 
inhibition of cell proliferation: the greatest effects were obtained 
by a single 8 Gy administration that induced a decrease in can-
cer cell proliferation of 24% at 24 h, 37% at 48 h, and 42% at 
72 h (Fig. 1A). These effects were paralleled by a dose-depen-
dent induction of apoptotic cell death after treatment with ion-
izing radiations (Fig. 1B). Moreover, we evaluated the effects 
of FTY720 on proliferation of MDA-MB361 cancer cells: 
Figure 1. antitumor effect of FTY720 and radiation in MDa-MB 361 cells. (A) cells were plated overnight and then exposed to radiation up to 8 Gy as 
indicated. Viability of cells was assessed by trypan blue assay. (B) Number of apoptotic cells was quantified by flow cytometry staining with annexin 
V/7aaD after 24 h of incubation. (C) cell viability of MDa-MB-361 treated with FTY720. Plated cells were treated with FTY720 at varying doses for the 
indicated times. (D) Number of apoptotic cells after drug administration at 24 h. Data are the average of three independent experiments performed in 
triplicate. P values were obtained using two-tailed t test. *P < 0.01.
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a dose-dependent inhibition of cell proliferation was indeed 
observed after treatment with the drug (Fig. 1C), which occurred 
together to apoptosis induction (Fig. 1D).
FTY720 enhances radiation-induced growth inhibition and 
apoptosis
Next we assessed whether FTY720 treatment could enhance 
radiation effects on MDA-MB 361 cells. The suboptimal dose of 
5 μM FTY720 was chosen for combinatory studies since lower 
concentrations resulted ineffective. Notably, FTY720 strongly 
increased the anti-proliferative effects of 8 Gy radiation (the 
greatest effects were obtained at 72 h: % of growth inhibition 
was of 42% for radiation, 42% for FTY720, and 90% for combi-
nation treatment [Fig. 2A]). Simultaneous exposure to FTY720 
synergistically interacted with ionizing radiation. The combina-
tion of FTY720 and ionizing radiation displayed a strong syner-
gistic effect against mammalian cancer cells (CI = 1.1).
These results suggest that FTY720 potentiates the growth-
inhibitory effects of radiation in breast cancer cells. To establish 
if the growth-inhibitory effects were dependent on apoptosis, 
we evaluated the proportion of apoptotic cells after treatment 
with FTY720 and radiation, using Annexin V/7-AAD stain-
ing and flow cytometry analysis. Results indicated that FTY720 
Figure 2. FTY720 sensitizes MDa-MB 361 cells to X-irradiation. Plated cells were pretreated for 1 h with FTY720 or vehicle at indicated concentration 
(5 uM), then exposed to 8 Gy X-irradiation. (A) cell viability of MDa-MB 361 cells was measured by trypan blue at indicated time. (B) apoptotic MDa-MB 
361 cells after 24 h of incubation were assessed by flow cytometry after annexin V/PI staining. columns and points, mean of three independent experi-
ment performed in triplicate; bars, *P < 0.01; (C–F) Observed nuclei morphological changes in MDa MB 361 cells after staining with DaPI using fluores-
cent microscopy with 40× magnification. (C) Untreated cells control; (D) treated cells with 5 uM FTY720; (E) treated cells with 8 Gy radiation; (F) treated 
cells with combination of FTY720 plus radiation.
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combined with radiation induced 40% of apoptosis and 7% of 
necrosis at 24 h in MDA-MB 361, which was significantly higher 
than radiation alone (17% in MDA-MB 361) or FTY720 alone 
(13% in MDA-361) (CI = 2). Hence these data indicate that 
apoptotic induction plays a significant role in FTY720-mediated 
radiosensitization of human breast cancer cells (Fig. 2B). More-
over, apoptosis induction in MDA-MB 361 cancer cells was 
assessed by the DAPI staining assay. Combination treatment led 
to shrinkage of nuclei, as shown in Figure 2C–F, further under-
lying the induction of apoptotic cell death.
Combination of FTY720 with RT induces MDA-MB 361 
cell accumulus in G
0
/
1
 phase
To assess whether FTY720 enhancement of radiation-induced 
growth inhibition was also dependent on cell cycle alterations, 
we analyzed the distribution of cell cycle phases by flow cytom-
etry. Interestingly, the two agents mediated different effects on 
cell cycle, since 24 h exposure to FTY720 caused a significant 
increase of cells at G
0
/G
1
 phase and a decrease of cells at S and 
G
2
/M phase, whereas radiation slightly reduced S phase. FTY720 
in combination with radiation enhanced blockage at G
0
/G
1
 cell 
cycle phase (Fig. 3A and B). Consistently with this finding, an 
increase in the expression of the cell cycle inhibitor p27Kip1 was 
observed after combined treatment but was not affected by the 
individual treatments (Fig. 3C).
FTY720 inhibits radiation-dependent activation of pro-
survival factors and potentiates RT-dependent caspase 3/7 
activation
To investigate the molecular mechanisms underlying the 
radio-sensitizing effects of FTY720, we analyzed the role of 
FTY720 plus radiation on the activation of signal transduction 
pathways involved in regulation of survival and apoptosis. Cells 
were treated with radiation (8 Gy) and FTY720 (5 μM) for 24, 
48, and 72 h and then the expression of phospho-ERK1/2, a 
member of the MAPK family, and phospho-AKT were assessed 
by western blot. Combination treatments reduced the expression 
of phospho-ERK1/2 compared with either FTY720 or radia-
tion alone. In our experimental setting, FTY720 in combination 
with radiation strongly decreased the levels of phospho-AKT 
especially if compared with radiation alone at 48 h time points. 
Furthermore, we examined the expression of the anti-apoptotic 
Figure 3. effects of FTY720 or ionizing radiation as individual agents or in combination on cell cycle distribution. (A) Perturbations of the cell cycle, 
analyzed by flow cytometry, after 24 h exposure to single or combined treatments. The data shown are representative of the combined mean of two 
independent experiments. (B) p27 immunoblot, at 24 h after treatment. standardization was performed with GaPDh stained in the same blots with 
anti-GaPDh antibody.
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protein survivin and observed a decline in its expression 48 h fol-
lowing combination treatment.
We evaluated caspase 3 and caspase 7 activity: a marked time-
dependent increase in the cleavage of caspase-7 was observed in 
cells treated with FTY720 (5 μM) in combination with radiation 
(8 Gy), 24 and 48 h after treatment. Moreover, pro-caspase 3 
expression was decreased by the combinatory treatment with a 
stronger effect after 48 h of treatment (Fig. 4).
Role of autophagy in FTY720/radiation-induced cell death
To assess if FTY720 could also modulate radiation effects on 
autophagy, we analyzed the regulation of autophagy after stain-
ing with mono-dansyl-cadaverine (MDC), a probe for detection 
of late autophagic vacuoles that is incorporated into multilamel-
lar bodies by both an ion trapping mechanism and interaction 
with membrane lipids.17 FTY720 (5 μM) plus ionizing radiation 
(8 Gy) treatment increased MDC fluorescence intensity, indicat-
ing that combination caused an accumulation of autophagosome 
likely due to the block of the autophagic flux determined by the 
combined treatment in MDA-MB361 cells (Fig. 5A). Moreover, 
we analyzed conversion of microtubule associated protein 1 
light chain 3 (LC3)-I to LC3-II, that is a marker of autophago-
some degradation, by western blotting with anti-LC3 antibody. 
FTY720 alone could induce this effect, but increased conversion 
from LC3-I to LC3-II was demonstrated after combined treat-
ment with radiation (Fig. 5B). This finding suggests that the 
combined treatment with FTY720 and radiation likely blocks 
autophagic processes switching the programmed cell death 
toward apoptosis.
Discussion
Radiation therapy is now of routine value after conservative 
surgery to reduce loco-regional tumor recurrence in breast can-
cer.18 Unfortunately, the efficacy of radiotherapy is often limited 
by the intrinsic cell resistance to ionizing radiation of tumor 
cells.19
In the last decade, the development of radiosensitizers have led 
to increased efficacy and reduced toxicity of radiation therapy. S1P 
is a potent sphingolipid mediator of diverse processes important 
for tumor cells, including cell growth, survival, migration, inva-
sion, and angiogenesis. SphK1 is upregulated in various human 
tumor tissue.20 The SphK1/S1P pathway contributes to cancer 
progression and leads to increased cell proliferation, impairment 
Figure 4. combination treatment regulates the apoptotic and survival pathways. Immunoblot of paKT/aKT and peRK/eRK, 24 and 48 h after individual 
or combination treatments. standardization was performed with α-tubuline measured in the same blots with anti-α-tubuline antibody. Moreover, 
immunoblot of cleaved caspase 7, pro-caspase 3, and survivin at time and conditions indicated are described. The protein loading control was per-
formed using GaPDh.
©
20
14
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
802 cancer Biology & Therapy Volume 15 Issue 6
of apoptosis, and oncogenic transformation.21 Furthermore, high 
levels of SphK1 expression and activity are associated with a poor 
prognosis in breast cancer.22 This information indicates that high 
SphK1 activity can protect against ionizing radiation and could 
induce radioresistance. Many therapeutic agents act against can-
cer cells by inducing apoptosis and resistance to cancer therapies, 
which usually involves intrinsic or extrinsic abrogation of the 
apoptotic machinery. Accumulating evidence has indicated that 
SphK1 could protect cancer cells from apoptosis;23 in addition, 
breast cancer cell radioresistance has been linked with sustained 
activation of SphK1.10 Therefore, a combination therapy based on 
a SphK1 inhibitor and radiation could provide a useful strategy 
for the treatment of therapeutic-resistant cancers.24
Here we report that targeting SphK1 with FTY720 poten-
tiated radiation-induced suppression of cell proliferation and 
induction of apoptosis. Our findings are in agreement with a 
recent work by Pchekectski et al.9 showing that FTY720 acts 
as a radiosensitizer on prostate cancer cell lines. It is also well 
accepted that S1P produced by activation of SphK1 is released 
from cells and stimulates its receptors that are linked to activa-
tion of AKT.25 The PI3/AKT pathway is implicated in radiore-
sistance of human tumor cells. Inhibition of the AKT pathway 
can modulate sensitivity of tumor cells to apoptosis to increase 
radiation-induced cell death.26,27 The reduction of S1P levels by 
FTY720 contributes to decreased phosphorylation of AKT in 
combined treatment with radiation, as we have shown by western 
blot analysis. Moreover, the levels of the anti-apoptotic protein 
survivin, which is increased in most malignancies and confers 
radiation resistance in cancer,28,29 was strongly decreased in cells 
treated with FTY720 plus radiation. It is therefore tempting 
to speculate that FTY720/radiation induced-apoptosis might 
be dependent on downregulation of survivin. Moreover, in the 
present study we report, together with the induction of apop-
tosis, the increased accumulation of autophagosome vesicles in 
cells treated with FTY720/radiation. It is well established that 
apoptosis is important in determining the outcome of chemo- 
and radiation therapy and can be triggered by anticancer drugs 
and radiation. However, apoptosis is not the unique form of cell 
death. Autophagy is an evolutionarily conserved catabolic pro-
cess for the degradation and recycling of cytosolic, long lived, 
or aggregated proteins, and excess or defective organelles, and is 
primarily a response to the stress by radiation and chemotherapy 
agents. Recently, different studies have suggested a dual role for 
autophagy in regulating cell death and it has recently emerged 
as a survival response of cancer cells to chemotherapy agents.30 
In this light, it has been reported that the autophagy induced by 
FTY720 worked as a protective function in ovarian cancer31 and 
acute lymphoblastic leukemia cells;32 on the other hand, a recent 
study on multiple myeloma cells has demonstrated the ability of 
FTY720 to induce autophagic cell death and apoptosis.33,34 This 
discrepancy may be attributable to the complex and diverse inter-
plays between autophagy and other mechanisms of cell death.35 
In our experimental setting, we found that the decrease in cell 
viability and the induction of apoptosis occurred together to the 
increase of autophagosome vesicles, as assessed by upregulation 
of apoptotic, i.e., cleaved caspase 7, and autophagic markers, i.e., 
cleaved LC3B. The regulatory pathways of autophagy and apop-
tosis share several molecules, among these PI3K/AKT/mTOR 
plays an important role in radiation-induced autophagy.36,37 
SIP is a potent inhibitor of ceramide-induced apoptosis but also 
induces autophagy, which indicates how the intracellular milieu 
can contribute to “deciding” between the two processes.
An explanatory cartoon of the effects of fingolimod on signal 
transduction pathways in our experimental model is reported in 
Figure 6.
On the basis of our results, it is possible to hypothesize that 
the combined treatment potentiates apoptosis occurrence and 
blocks the autophagy flux causing a paradoxical increase of 
autophagosomes in breast cancer cells that decide to die through 
apoptosis. On the other hand, autophagy can facilitate apoptosis 
Figure 5. combination treatment induces autophagosome accumulation in MDa-MB-361 cells. (A) To quantify fluorescent compound MDc incorpo-
rated in MDa-MB-361, cells autophagy test was used as described in Methods. *P > 0.05; **P = 0.02. (B) Western blot analysis was performed for Lc3B. 
The equal loading of protein was confirmed by probing with GaPDh.
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by maintaining ATP levels during starvation to promote ATP-
dependent apoptotic processes in embryonic cells.38
In conclusion, our findings indicate that FTY720 induces 
radiosensitization of breast cancer cells, providing the first pre-
clinical framework for a potential clinical use of this agent, in 
combination with radiotherapy, to overcome radioresistance and 
potentially improve the outcome of breast cancer patients.
Materials and Methods
Cell lines and drug
Human breast cancer cells (MDA-MB-361) were obtained 
from the American Type Culture Collection and maintained as 
adherent monolayer cultures previously reported.39
FTY720(Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol 
hydrochloride) was purchased from Selleck Chemicals, and 
stored as 100 mM stock solution in DMSO, protected from light 
at –20 °C. The drug was diluted in fresh media prior to each 
experiment.
Radiation treatment
Exponentially growing tumor cells were plated in 100 mm tis-
sue culture dishes or in 6-well plates, allowed to attach for 24 h, 
and treated with 3 different doses of radiation (2, 5, and 8 Gy) at 
room temperature, at the dose of 1, 8 Gy/min and Source Surface 
Distance (SSD) of 80 cm2, by using a 6 MV photon linear accel-
erator (CLINAC 600 Varian) as previously reported.40
Trypan blue viability assay
Cell lines were plated on 6-well plates at the density of 
5.0 × 104/well. Twenty-four hours later, cells were left untreated, 
irradiated with different doses of radiation or treated with vari-
ous concentrations of FTY720; for combination treatments, 
FTY720 was added 1 h before irradiation. After 24, 48, and 72 h 
incubation, cell survival was determined with 0.2% trypan blue 
solution.
Analysis of apoptosis
Cells were treated as previously described with ionizing radia-
tion, FTY720, or combinations; after 24 h, cells were harvested, 
washed twice with cold 1× PBS and stained with Annexin 
V-PE/7-aminoactinomycin D (7AAD) solution (BD Bioscience) 
as indicated by the manufacturer41 and then analyzed by flow 
cytometery (FACS-Calibur, BD Bioscience).
Apoptosis induction was also evaluated by fluorescence dye 
staining using DAPI to identify the condensation and fragmenta-
tion of nucleic DNA of apoptotic cells.
Cancer cells were treated with the combination of FTY720 
and ionizing radiation (5 μM and 8 Gy respectively) and incu-
bated for 72 h. The culture medium was removed and cells 
were rinsed by 1× PBS and finally fixed using 50 μL methanol. 
Subsequently 50 μL of DAPI (Invitrogen, Life Technologies) 
was added to cells at the final concentration of 1 μg/mL. The 
stained nucleic DNA was captured under fluorescence micros-
copy at a magnitude of 40× (LEICA DM4000 B LED, Leica 
Microsystems).
Figure 6. explanatory cartoon of fingolimod effects on signal transduction pathways. sphingosine kinase (sphK1) is a key regulator of the dynamic 
ceramide/sphingosine-1-phosphate (sP1) rheostat balance which is important in the pathological cancerogenesis, progression, metastasis process and 
resistance to treatments. FTY720 acts as a sphK1 antagonist reducing sP1 levels with perturbation of PI3K/aKT/mTor pathway involved in apoptosis and 
autophagy of the cancer cells and modulating sensitivity of tumor cells to radiation-induced cell death.
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